Compliance Handbook for Pharmaceuticals, Medical Devices, and Biologics (Drugs and the Pharmaceutical Sciences)

(8)
Compliance Handbook for Pharmaceuticals, Medical Devices, and Biologics (Drugs and the Pharmaceutical Sciences) image
ISBN-10:

0367394766

ISBN-13:

9780367394769

Edition: 1
Released: Oct 02, 2019
Publisher: CRC Press
Format: Paperback, 704 pages
Related ISBN: 9780824740788

Description:

This text lists the necessary steps for meeting compliance requirements during the drug development process. It presents comprehensive approaches for validating analytical methods for pharmaceutical applications.

Best prices to buy, sell, or rent ISBN 9780367394769




Frequently Asked Questions about Compliance Handbook for Pharmaceuticals, Medical Devices, and Biologics (Drugs and the Pharmaceutical Sciences)

You can buy the Compliance Handbook for Pharmaceuticals, Medical Devices, and Biologics (Drugs and the Pharmaceutical Sciences) book at one of 20+ online bookstores with BookScouter, the website that helps find the best deal across the web. Currently, the best offer comes from and is $ for the .

The price for the book starts from $63.94 on Amazon and is available from 16 sellers at the moment.

If you’re interested in selling back the Compliance Handbook for Pharmaceuticals, Medical Devices, and Biologics (Drugs and the Pharmaceutical Sciences) book, you can always look up BookScouter for the best deal. BookScouter checks 30+ buyback vendors with a single search and gives you actual information on buyback pricing instantly.

As for the Compliance Handbook for Pharmaceuticals, Medical Devices, and Biologics (Drugs and the Pharmaceutical Sciences) book, the best buyback offer comes from and is $ for the book in good condition.

The Compliance Handbook for Pharmaceuticals, Medical Devices, and Biologics (Drugs and the Pharmaceutical Sciences) book is in very low demand now as the rank for the book is 6,713,001 at the moment. A rank of 1,000,000 means the last copy sold approximately a month ago.

Not enough insights yet.